The efficacy of Lacticaseibacillus paracasei MSMC39-1 and Bifidobacterium animalis TA-1 probiotics in modulating gut microbiota and reducing the risk of the characteristics of metabolic syndrome: A randomized, double-blinded, placebo-controlled studyOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This randomized, double-blind, placebo-controlled trial tested whether two probiotic strains reduce metabolic syndrome risk factors and reshape the gut microbiota. Participants took Lacticaseibacillus paracasei MSMC39-1 and Bifidobacterium animalis TA-1 or a matching placebo for 12 weeks. Blood chemistry, anthropometrics, and stool were measured at baseline and 12 weeks. Gut microbiota was profiled by 16S rRNA V4 sequencing, with function predicted by PICRUSt2. The primary outcome was change in LDL cholesterol.
Who was studied?
The trial enrolled 60 adults with metabolic syndrome risk factors from an outpatient clinic in Thailand; 58 completed and were analyzed. The probiotics group had 31 participants (mean age 42.3 years) and placebo had 27 (mean age 43.9 years). About 70 percent were female in both groups. Eligibility required age 18-60 and at least three metabolic syndrome criteria such as elevated waist circumference, blood pressure, triglycerides, or fasting glucose, or low HDL. People with diabetes, established hypertension, and recent antibiotic or probiotic use were excluded.
What were the most important findings?
LDL cholesterol fell far more with probiotics than placebo, a difference of 39.97 mg/dl (p below 0.001). The probiotics group also significantly reduced body weight (about 3.90 kg), body mass index, waist circumference, systolic blood pressure, total cholesterol, and triglycerides, while HDL rose. No adverse events occurred. Beta diversity shifted significantly after probiotics (PERMANOVA p = 0.002). Blautia, Roseburia, Collinsella, and Ruminococcus became more prevalent, while Proteobacteria and Prevotellaceae decreased.
What are the greatest implications of this study?
The trial indicates these two probiotic strains can lower LDL cholesterol and other metabolic syndrome risk factors over 12 weeks. Enrichment of short-chain-fatty-acid-linked genera and predicted pathways for unsaturated fatty acid biosynthesis and pyruvate metabolism offer plausible mechanisms. The sample was modest, single-country, and 12 weeks long, so durability and generalizability remain open. The results support probiotics as a possible adjunct to diet and exercise, not a replacement, for managing cardiovascular risk.